Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | USP10 | Q14694 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500826 | 1.00 | KMT2A (0.51) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL3601937 | 0.91 | KMT2A (0.57) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL3071975 | 0.91 | KMT2A (0.57) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL3166353 | 0.88 | TSHR (0.52) | ALDH1A1RAB9ALMNASTAT3 | |
| SCHEMBL4882206 | 0.88 | TSHR (0.52) | ALDH1A1RAB9ALMNASTAT3 | |
| SCHEMBL2536459 | 0.84 | STAT3 (0.54) | KMT2AALDH1A1MAPTRAB9APKM | |
| SCHEMBL2536457 | 0.84 | STAT3 (0.54) | KMT2AALDH1A1MAPTRAB9APKM | |
| SCHEMBL3126940 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL3126932 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL29493914 | 0.83 | MAPT (0.54) | KMT2AALDH1A1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2096109-A1 | CARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-2096109-A1 | CARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | KMT2A 3440/4885ALDH1A1 1850/4885MAPT 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.